Patents Examined by Kay K. Kim
-
Patent number: 5463028Abstract: This invention provides a compound comprising a methyl ecgonine group chemically attached to a phenylphosphonic group which is an analog to an intermediate of the hydrolysis transition-state of a cocaine benzoyl ester group. This invention also provides such analogs linked to carrier proteins, and antibodies thereto.Type: GrantFiled: April 3, 1992Date of Patent: October 31, 1995Assignee: The Trustees of Columbia University in the City of New YorkInventors: Donald W. Landry, Kang Zhao
-
Patent number: 5462735Abstract: Protection of ruminants against bacterial pneumonia caused by Pasteurella haemolytica has been achieved with a subunit vaccine. The vaccine contains two principle components; capsular polysaccharide of P. haemolytica and a synthetic adjuvant, muramyl dipeptide. This vaccine prevented bacterial infection of the lungs of vaccinated animals upon challenge with P. haemolygica. In contrast, animals that were not vaccinated or animals that were vaccinated with only capsular polysaccharide alone had severe lesions and high concentrations of P. haemolytica in the lung.Type: GrantFiled: June 10, 1993Date of Patent: October 31, 1995Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Kim A. Brogden, Louis Chedid
-
Patent number: 5455032Abstract: This invention relates to compositions useful for inducing immunoprotection against infections by pathogenic organisms containing phosphocholine antigens, including Streptococcus pneumoniae and other microorganisms that have a phosphocholine antigen component of their membranes or capsids. This invention also relates to vaccines and methods for inducing immunoprotection against infection by these pathogenic organisms.Type: GrantFiled: July 29, 1993Date of Patent: October 3, 1995Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: James J. Kenny, Dan L. Long
-
Patent number: 5443832Abstract: A method for generating antigen-sensitized Ig-A-producing lymphoblasts in a mammal, using an immunogen comprising an antigen or antigen mixture in association with hydroxylated calcium phosphate (hydroxy apatite) is administered to a mucosal surface of the mammal.Type: GrantFiled: April 16, 1990Date of Patent: August 22, 1995Assignee: Institut Swisse de Recherches Experimentales sur le CancerInventors: Helen M. Amerongen, Marian R. Neutra, Jean-Pierre Kraehenbuhl
-
Patent number: 5441867Abstract: Pre-activated stable protein reagents are provided. The reagents can be made by reaction of the protein and a heterobifunctional linker and have extended stability especially after lyophilisation. The reagents can be used in assay kits to form conjugates with proteins e.g. antibodies or polynucleotides e.g. oligonucleotides probes.Type: GrantFiled: January 7, 1992Date of Patent: August 15, 1995Assignee: Zeneca LimitedInventors: Andrew J. Garman, John R. Parker
-
Patent number: 5440023Abstract: A method for making a valproic acid derivative comprising a functionalized spacer arm attached to a .delta. carbon atom of a valproic acid molecule is disclosed. The method proceeds by attaching a spacer arm joined to an inorganic moiety to a valproic acid precursor to make an alkylated compound, derivatizing the alkylated compound in a liquid medium to make the valproic acid derivative, and then separating the valproic acid derivative from the liquid medium. The valproic acid derivative can be used to make an immunoreactive valproic acid conjugate.Type: GrantFiled: September 18, 1992Date of Patent: August 8, 1995Assignee: Beckman Instruments, Inc.Inventors: Anthony K. Cheng, Thomas S. Dobashi
-
Patent number: 5436157Abstract: A substantially purified intra-acrosomal human sperm antigen useful in a contraceptive vaccine is disclosed herein. The antigen remains associated with human sperm after the acrosome reaction. In particular, it remains associated with the inner and outer acrosomal membranes. Modified antigens and fragments thereof prepared by protein modification techniques are also disclosed as well as methods for purifying and using the antigens. Also disclosed are monoclonal and polyclonal antibodies to the antigen and methods of making and using such antibodies. Methods of use include purification of the antigen or use in various diagnostic techniques. Also disclosed are cDNA, expression vectors, and transformed microorganisms that produce the antigen.Type: GrantFiled: February 16, 1990Date of Patent: July 25, 1995Assignee: The University of Virginia Alumni Patents FoundationInventors: John C. Herr, Richard M. Wright
-
Patent number: 5432260Abstract: Polypeptide backbones containing sugar residues at repetitive intervals are capable of binding the mannose receptor when said sugars are mannosyl, fucosyl, or N-acetyl glucosamine residues. These peptides are of the formulaX--(Z(Sa)AA.sub.n1).sub.n2 --Y (1)wherein Sa represents a mannose, fucose, glucose or N-acetylglucosamine residue optionally coupled to a linker moiety; Z is the residue of an amino acid to which S is coupled; each AA is independently the residue of an additional amino acid, n1 is an integer=1, 2 or 3; n2 is 3-15, and X and Y are noninterfering substituents. They are useful in the treatment of various diseases mediated by macrophage activity and proliferation.Type: GrantFiled: May 3, 1991Date of Patent: July 11, 1995Assignee: Washington UniversityInventor: Philip D. Stahl
-
Patent number: 5427782Abstract: Method for immunizing against respiratory vital infection by administering intranasally an immunogenically effective amount of a vital envelope subunit vaccine, preferably comprising a mixture of the vital envelope glycoproteins complexed with a lipid.Type: GrantFiled: May 20, 1992Date of Patent: June 27, 1995Assignee: Molecular Engineering Associates, Inc.Inventors: Richard W. Compans, Ranjit Ray
-
Patent number: 5422281Abstract: A novel bidentate conjugate has two different chemical moieties, or bidentate members, attached through an adequate spacer moiety. Each bidentate member acts as a small molecule ligand and is capable of specifically binding to a different macromolecular substance. The bidentate members are relatively small molecules, usually less than about 7,000 Daltons in size. The spacer moiety is selected so that both bidentate members can simultaneously bind to their respective specific binding partners. Where the specific binding partners are multivalent, large complexes can be formed. The formation of these complexes can be inhibited by the presence of an unconjugated monovalent bidentate member, such as free analyte from a test sample. The bidentate is of particular use in turbidimetric or nephelometric inhibition immunoassay procedures.Type: GrantFiled: July 31, 1992Date of Patent: June 6, 1995Assignee: Beckman Instruments, Inc.Inventors: Paul C. Harris, Chan S. Oh
-
Patent number: 5407834Abstract: The present invention is directed to a fluorescence polarization assay for phencyclidine and phencyclidine derivatives, to the various components needed for preparing and carrying out such an assay, and to methods of making these components. Specifically, tracers, immunogens and antibodies are disclosed, as well as methods for making them, and a reagent kit containing them. The tracers and the immunogens are made from substituted phencyclidine compounds. A fluorescein moiety is included in the tracer, while a poly(amino acid) forms a part of the immunogen. The assay is conducted by measuring the degree of polarization retention of plane polarized light that has been passed through a sample containing antiserum and tracer.Type: GrantFiled: April 27, 1992Date of Patent: April 18, 1995Assignee: Abbott LaboratoriesInventors: Robert E. Dubler, Mary P. Frintner, Jonathan Grote, Gregg A. Hadley, David J. Hawksworth, Hal D. Hopkins, Daniel S. Nam, Frank S. Ungemach, Larry K. Wray
-
Patent number: 5399347Abstract: The present invention is directed to a method and pharmaceutical formulations for the treatment of autoimmune arthritis and animal models therefore in mammals, including humans, by the oral, enteral or by-inhalation administration of whole collagen protein or biologically active peptide fragments of collagen.Type: GrantFiled: September 25, 1992Date of Patent: March 21, 1995Assignee: Autoimmune, Inc.Inventors: David E. Trentham, Howard L. Weiner, David A. Hafler
-
Patent number: 5399710Abstract: Novel labeling reagents are useful for radiolabeling proteins such as antibodies with radionuclide metals such as .sup.99m Tc, .sup.186 Re, and .sup.188 Re. The reagents are of the following formula: ##STR1## wherein: each X is independently chosen from O, S, NH, or NR.sub.2, wherein R.sub.2 is a protecting group or an electron withdrawing group;R.sub.1 represents a protecting group, wherein each R.sub.1 is a separate protecting group or the two R.sub.1 symbols are taken together to represent a single protecting group; andeach T is independently chosen from hydrogen, lower alkyl groups of from 1 to about 6 carbon atoms, electron withdrawing groups, and lower alkyl groups of from 1 to about 6 carbon atoms substituted with electron withdrawing group(s).Type: GrantFiled: December 22, 1992Date of Patent: March 21, 1995Assignee: NeoRx CorporationInventors: Sudhakar Kasina, Ananthachari Srinivasan, James Sanderson, Alan R. Fritzberg
-
Patent number: 5387578Abstract: Conjugate of general formula 1:[A--O--W-Z].sub.a -T 1wherein the moity A--O--is the residue of drug of formula A--O--H in which --O--H is a primary or secondary hydroxyl group; a is an integer of from 1 to 30; W is a group of general formula 2: ##STR1## wherein b is an integer of from 1 to 4, B represents a C.sub.1 -C.sub.3 alkylene group and R.sub.1 and R.sub.2 each independently represent hydrogen, halogen, alkyl, phenyl or substituted phenyl; Z is a spacer group and T is a carrier moiety.Type: GrantFiled: April 3, 1992Date of Patent: February 7, 1995Assignee: Farmitalia Carlo Erba S.r.l.Inventors: Francesco Angelucci, Laura Bersani, Michele Caruso, Marina Ripamonti, Daniela Ruggieri, Antonino Suarato
-
Patent number: 5378636Abstract: Methods are disclosed for inactivating interfering binding proteins in a immunoassay for a member of a specific binding pair (sbp). The method comprises including in an assay medium containing a sample suspected of containing an sbp member and an interfering binding protein an effective amount of a water soluble compound having two substituted or unsubstituted phenyl groups linked to a common atom. When the sbp member or its sbp partner has two phenyl groups linked to a common atom, the compound has a number of groups other than hydrogen attached to the phenyl groups and the atom that differs by at least two from the number of such groups on the sbp member. When the sbp member or its sbp partner has two phenyl groups linked to a common atom and the binding protein is not an antibody, the compound has only one group other than hydrogen attached to a phenyl group or the common atom.Type: GrantFiled: August 12, 1993Date of Patent: January 3, 1995Assignee: Syntex (U.S.A.) Inc.Inventors: Mae W.-L. Hu, Kirk Schulkamp, Cheng-I Lin, Edwin F. Ullman
-
Patent number: 5378815Abstract: A process is disclosed for treating cancer by the process of indirect targeted immunocytolysis, which comprises conjugating an immunogenic sensitizing agent to a targeting agent which is capable of binding to aberrant cells, such as cancer cells in a human or animal host. The conjugate is then introduced into the body of an animal or human which has previously been actively immunized against the sensitizing agent or concomitantly treated with the appropriate antibody (passive immunization). Binding of the conjugate to the object cells occurs and is accompanied by the binding of antibodies produced against the sensitizing agent. This results in triggering of a complement cascade and/or an antibody-dependent T-cell-mediated response leading to cell destruction. Also disclosed are the novel targeting agent/sensitizing agent conjugates for use in the process. Agents comprise autocrine differentiation-inhibiting factor/toxoid conjugates.Type: GrantFiled: February 10, 1992Date of Patent: January 3, 1995Assignees: National Research Council Canada, Consel National de Recherche ScientifiqueInventors: Velibor Krsmanovic, Jon P. Durkin, Jagmohan L. Bhasin, Jean-Michel Biquard, Phillip A. Macdonald, James F. Whitfield
-
Patent number: 5370872Abstract: The present invention relates to a method of producing an E. coli vaccine and to the vaccine produced thereby. The method involves purifying lipopolysaccharide from E. coli expressing complete O-polysaccharide sidechains;isolating the O-polysaccharide region of the lipopolysaccharide molecule by hydrolysis in dilute acetic acid and purifying it essentially free of lipid A; and covalently coupling lipid A-free O-polysaccharide via at least one hydroxyl or carboxyl group of the polysaccharide to a carrier protein. Polyvalent vaccines are prepared by combining two or more monovalent vaccines for different serotypes prepared according to the present invention. The present also relates to conjugates used in the vaccines. The conjugates of the present invention are the O-polysaccharide region of an E. coli lipoplysaccharide molecule covalently coupled to a carrier protein.Type: GrantFiled: August 12, 1991Date of Patent: December 6, 1994Assignee: Swiss Serum and Vaccine Institute BerneInventors: Stanley J. Cryz, Emil P. Furer
-
Patent number: 5371197Abstract: A conjugate immunogen, having polysaccharide moieties derived from bacterial sources, provides a multivalent vaccine with a low protein to polysaccharide ratio. The vaccine reduces complications associated with injection of protein immunogens due to pyrogenic responses, such as swelling and pain, and is particularly suitable for administration to infants.Type: GrantFiled: September 24, 1991Date of Patent: December 6, 1994Assignee: Merck & Co., Inc.Inventors: Stephen Marburg, Richard L. Tolman
-
Patent number: 5360897Abstract: An immunogenic conjugate which is the reductive amination product of an immunogenic capsular polymer fragment having at least one reducing group and derived from a bacterial capsular polymer of a bacterial pathogen, and a bacterial toxin or toxoid. The invention also relates to methods for the preparation of the conjugates, a vaccine containing the conjugates which elicits effective levels of anti-capsular polymer antibodies in humans. Also disclosed are methods for inducing active immunization against systemic infection in young mammals caused by bacterial pathogens comprising the administration of an immunogenic amount of the above-described conjugate. In a preferred embodiment, the capsular polymer fragment prior to conjugation has at least one aldehyde group at each end of the fragment. The final conjugate made with such capsular polymers has a lattice or network structure, and provides extremely high levels of anti-capsular polymer antibodies in infants.Type: GrantFiled: January 9, 1992Date of Patent: November 1, 1994Assignee: The University of RochesterInventors: Porter W. Anderson, Ronald J. Eby
-
Patent number: 5360719Abstract: A patient's blood sample is incubated with an antigen and tested for lymphocyte response, i.e. an activation of lymphocytes and/or a conversion of lymphocytes to lymphoblasts, which indicates prior exposure of the patient to the antigen. A positive response indicates the presence of prior exposure to prior diseases or clinical conditions such as parasitic diseases, tuberculosis, salmonellosis, gonorrhea, fungal infections, rickettsial infections, Lyme disease or allergens. Whole blood from the patient is incubated with the antigen of the disease or condition for which the patient is being tested. After a suitable time, a fluorescent dye or colorant which has an affinity for a discriminant characteristic of the activated lymphocytes or lymphoblasts, such as: intracellular calcium; surface activation antigens such as transferrin receptor; HLA-Dr; Leu-23; and the like.Type: GrantFiled: September 30, 1992Date of Patent: November 1, 1994Inventors: Robert A. Levine, Stephen C. Wardlaw